NovMetaPharma Co., Ltd. (XKON:229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,750.00
+760.00 (9.51%)
At close: May 14, 2026
Market Cap112.36B +7.6%
Revenue (ttm)1.30B +21.4%
Net Income408.03M
EPS120.00
Shares Out12.84M
PE Ratio72.92
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,661
Average Volume7,903
Open9,070.00
Previous Close7,990.00
Day's Range8,000.00 - 9,070.00
52-Week Range6,800.00 - 17,890.00
Beta0.18
RSI44.22
Earnings Daten/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic and fibrotic diseases in South Korea. It is developing Cyclo-Z, which is in phase 2 clinical stage; and CHP that is in phase 1 clinical stage for the treatment of diabetic kidney disease, obesity, and rare conditions, including FSHD and DMD. The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015. NovMetaPharma Co., Ltd. was incorporated in 2010 and is headquartered in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile